TapewireFind a company

person · Reporting owner

Grimes Scott D.

Disclosed activity across 4 companies

Tapewire entity
122482
SEC CIK
0001617486

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Cardlytics, Inc.CDLX · Entity 7603DirectorNovember 08, 2022November 10, 2022
Evergy, Inc.EVRG · Entity 3282DirectorApril 01, 2020April 02, 2020
Plum Acquisition Corp. IIIAPTMU · Entity 83854DirectorJuly 27, 2021July 27, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cardlytics, Inc.

Report date November 08, 2022 · Filed November 10, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect248,779 Reported balance After 2022-11-08 transaction · row 1
1 source row

Row 1 · 2022-11-08 · Sale · Disposed 6 · Balance 248,779

F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022.

Common StockSEC Table I · non-derivativeIndirectSee Footnote55,832 Reported balance Holding disclosure · report date 2022-11-08 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 55,832

F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes.

Common StockSEC Table I · non-derivativeIndirectSee Footnote53,112 Reported balance Holding disclosure · report date 2022-11-08 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 53,112

F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for performance stock units that vested on October 6, 2022.

F2: The reportable securities are held by the UTMA Custodial account fbo Pierce Grimes.

F3: The reportable securities are held by the 2013 Scott Grimes GRAT UAD.

Evergy, Inc.

Report date April 01, 2020 · Filed April 02, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Director Deferred Share UnitsSEC Table II · derivative / convertible securityDirect13,666 Reported balance After 2020-04-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-04-01 · Grant · Acquired 455 · Balance 13,666

F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents.

Common StockSEC Table I · non-derivativeDirect788 Reported balance Holding disclosure · report date 2020-04-01 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 788

Filing footnotes · ownership attribution and instrument terms

F1: Director Deferred Share Units represent the right to receive one share of Evergy, Inc. ("Evergy") common stock, plus, if applicable, stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F2: Director Deferred Share Units received as partial payment of retainer fees that have been deferred pursuant to elections made by the reporting person.

F3: Includes 122 deferred share units acquired through the reinvestment of dividend equivalents.

Plum Acquisition Corp. III

Report date July 27, 2021 · Filed July 27, 2021

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

GREAT PLAINS ENERGY INC

Report date June 04, 2018 · Filed June 05, 2018

Section 16 reporting ended · disclosed 2018-06-05. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-06-04 transaction · row 1
1 source row

Row 1 · 2018-06-04 · Disposition to issuer · Disposed 1,318 · Balance 0

F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange.

Director Deferred Share UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2018-06-04 · Disposition to issuer · Disposed 11,970 · Balance 0

F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger ("Merger Agreement") dated as of July 9, 2017 by and among Great Plains Energy Incorporated ("Great Plains Energy"), Westar Energy, Inc., Evergy, Inc. ("Evergy") (formerly Monarch Energy Holding, Inc.), King Energy, Inc., and for certain limited purposes, GP Star, Inc. in exchange for shares of Evergy common stock at an exchange ratio of 0.5981 for each Great Plains Energy share on the effective date of the merger. On the effective date of the merger, the closing price of Great Plains Energy's common stock was $31.99 per share, and Evergy's common stock had not yet commenced trading on the New York Stock Exchange.

F2: Director Deferred Share units are granted under the Long-Term Incentive Plan. Each unit represents the right to receive one share of Great Plains Energy Common Stock, plus stock reflecting reinvested dividends. Units are converted to stock and distributed following termination of service on the Board pursuant to elections made by the reporting person.

F3: The Great Plains Energy Director Deferred Share units were exchanged for Evergy Director Deferred Share units pursuant to the Merger Agreement at an exchange ratio of 0.5981 for each Great Plains Energy share.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 09, 2020 Filed Nov 11, 2020 01:45 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 350 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000284 · wf-form4_160505910058463.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,140

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.

Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:37 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 764 $76.72 $58,614.08
Disclosure

SEC source: 0001666071-20-000281 · wf-form4_160443945994078.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 107,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $76.44 to $77.16, inclusive.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:37 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,036 $75.74 $78,466.64
Disclosure

SEC source: 0001666071-20-000281 · wf-form4_160443945994078.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 107,876

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $75.39 to $76.33, inclusive.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:37 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 200 $74.66 $14,932.00
Disclosure

SEC source: 0001666071-20-000281 · wf-form4_160443945994078.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 108,912

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $74.29 to $75.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2),(4) and (5) to this Form 4.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
October 16, 2020 Filed Oct 19, 2020 20:33 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 400 $82.49 $32,996.00
Disclosure

SEC source: 0001666071-20-000271 · wf-form4_160313957722132.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 109,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $82.33 to $82.91, inclusive.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
October 16, 2020 Filed Oct 19, 2020 20:33 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 500 $81.32 $40,660.00
Disclosure

SEC source: 0001666071-20-000271 · wf-form4_160313957722132.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 109,512

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $81.17 to $81.67, inclusive.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
October 16, 2020 Filed Oct 19, 2020 20:33 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,100 $80.40 $88,440.00
Disclosure

SEC source: 0001666071-20-000271 · wf-form4_160313957722132.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 110,012

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $80.05 to $80.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
October 02, 2020 Filed Oct 5, 2020 20:30 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 200 $72.25 $14,450.00
Disclosure

SEC source: 0001666071-20-000269 · wf-form4_160192983754801.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 111,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $72.10 to $72.40, inclusive.

F2 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
October 02, 2020 Filed Oct 5, 2020 20:30 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,700 $71.27 $121,159.00
Disclosure

SEC source: 0001666071-20-000269 · wf-form4_160192983754801.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 111,312

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $70.94 to $71.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.

F2 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
October 02, 2020 Filed Oct 5, 2020 20:30 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 100 $69.87 $6,987.00
Disclosure

SEC source: 0001666071-20-000269 · wf-form4_160192983754801.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 113,012

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
September 16, 2020 Filed Sep 18, 2020 20:13 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 154 $74.05 $11,403.70
Disclosure

SEC source: 0001666071-20-000263 · wf-form4_160045996986987.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 113,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $73.92 to $74.30, inclusive.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
September 16, 2020 Filed Sep 18, 2020 20:13 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 800 $73.15 $58,520.00
Disclosure

SEC source: 0001666071-20-000263 · wf-form4_160045996986987.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 113,266

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $72.87 to $73.46, inclusive.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
September 16, 2020 Filed Sep 18, 2020 20:13 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,046 $72.18 $75,500.28
Disclosure

SEC source: 0001666071-20-000263 · wf-form4_160045996986987.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 114,066

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $71.80 to $72.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4.

F3 · ownership.nature: The Reporting Person is the trustee of the GRAT.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 20:49 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 200 $79.92 $15,984.00
Disclosure

SEC source: 0001666071-20-000262 · wf-form4_159916613678362.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 115,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $79.84 to $80.00, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 20:49 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,000 $78.93 $78,930.00
Disclosure

SEC source: 0001666071-20-000262 · wf-form4_159916613678362.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 115,312

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $78.49 to $79.47, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 20:49 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 800 $77.93 $62,344.00
Disclosure

SEC source: 0001666071-20-000262 · wf-form4_159916613678362.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 116,312

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $77.49 to $78.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), and (5) to this Form 4.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
August 27, 2020 Filed Aug 28, 2020 20:08 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,500 $81.80 $122,700.00
Disclosure

SEC source: 0001666071-20-000258 · wf-form4_159864528843893.xml · nonDerivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,790

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for PSUs that vested on August 26, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $81.61 to $81.99, inclusive.

Read SEC document
August 27, 2020 Filed Aug 28, 2020 20:08 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,850 $87.59 $337,221.50
Disclosure

SEC source: 0001666071-20-000258 · wf-form4_159864528843893.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,290

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for PSUs that vested on August 26, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $80.6372 to $81.56, inclusive.

Read SEC document
August 27, 2020 Filed Aug 28, 2020 20:08 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 3,810 $80.25 $305,752.50
Disclosure

SEC source: 0001666071-20-000258 · wf-form4_159864528843893.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,140

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for PSUs that vested on August 26, 2020.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $79.64 to $80.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4.

Read SEC document
August 26, 2020 Filed Aug 28, 2020 20:08 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionPerformance Stock Unit · Derivative 19,687 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000258 · wf-form4_159864528843893.xml · derivative · entry 6

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,687

Underlying: Common Stock · 19,687 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F7 · derivative.exercise_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the stock price target ("stock price tranche"). Fifty percent (50%) of the shares subject to the stock price tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019. Twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU vested on February 26, 2020, 6 months after the Certification. The final twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU vested on August 26, 2020, 12 months after the Certification.

F7 · derivative.expiration_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the stock price target ("stock price tranche"). Fifty percent (50%) of the shares subject to the stock price tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019. Twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU vested on February 26, 2020, 6 months after the Certification. The final twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU vested on August 26, 2020, 12 months after the Certification.

Read SEC document
August 26, 2020 Filed Aug 28, 2020 20:08 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 19,687 Not disclosed Not disclosed
Disclosure

SEC source: 0001666071-20-000258 · wf-form4_159864528843893.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 244,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 17, 2020 Filed Aug 18, 2020 20:07 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,300 $81.73 $106,249.00
Disclosure

SEC source: 0001666071-20-000255 · wf-form4_159778126535033.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 117,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $81.39 to $82.02, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
August 17, 2020 Filed Aug 18, 2020 20:07 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 700 $79.54 $55,678.00
Disclosure

SEC source: 0001666071-20-000255 · wf-form4_159778126535033.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 118,412

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $79.03 to $79.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
August 13, 2020 Filed Aug 13, 2020 23:17 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 69 $79.27 $5,469.63
Disclosure

SEC source: 0001666071-20-000244 · wf-form4_159736064092108.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,263

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs granted on August 11, 2020.

Read SEC document
August 11, 2020 Filed Aug 13, 2020 23:17 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionRestricted Stock Units · Derivative 166 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000244 · wf-form4_159736064092108.xml · derivative · entry 5

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 166 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.

F4 · derivative.exercise_date: The RSUs are immediately vested.

F4 · derivative.expiration_date: The RSUs are immediately vested.

Read SEC document
August 11, 2020 Filed Aug 13, 2020 23:17 UTC Cardlytics, Inc. CDLX · Entity 7603 GrantRestricted Stock Units · Derivative 166 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000244 · wf-form4_159736064092108.xml · derivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166

Underlying: Common Stock · 166 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.

F4 · derivative.exercise_date: The RSUs are immediately vested.

F4 · derivative.expiration_date: The RSUs are immediately vested.

Read SEC document
August 11, 2020 Filed Aug 13, 2020 23:17 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 166 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000244 · wf-form4_159736064092108.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,332

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.

Read SEC document
August 03, 2020 Filed Aug 4, 2020 22:53 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 634 $72.19 $45,768.46
Disclosure

SEC source: 0001666071-20-000236 · wf-form4_159658138118579.xml · nonDerivative · entry 5

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 119,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $71.96 to $72.66, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
August 03, 2020 Filed Aug 4, 2020 22:53 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 100 $70.66 $7,066.00
Disclosure

SEC source: 0001666071-20-000236 · wf-form4_159658138118579.xml · nonDerivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 119,746

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
August 03, 2020 Filed Aug 4, 2020 22:53 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 666 $70.15 $46,719.90
Disclosure

SEC source: 0001666071-20-000236 · wf-form4_159658138118579.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 119,846

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $69.59 to $70.56, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
August 03, 2020 Filed Aug 4, 2020 22:53 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 400 $68.62 $27,448.00
Disclosure

SEC source: 0001666071-20-000236 · wf-form4_159658138118579.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 120,512

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $68.31 to $69.23, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
August 03, 2020 Filed Aug 4, 2020 22:53 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 200 $66.92 $13,384.00
Disclosure

SEC source: 0001666071-20-000236 · wf-form4_159658138118579.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 120,912

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $66.45 to $67.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6) to this Form 4.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
July 16, 2020 Filed Jul 20, 2020 22:48 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 300 $78.62 $23,586.00
Disclosure

SEC source: 0001666071-20-000210 · wf-form4_159528529619625.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 121,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $78.41 to $78.85, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
July 16, 2020 Filed Jul 20, 2020 22:48 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,400 $77.85 $108,990.00
Disclosure

SEC source: 0001666071-20-000210 · wf-form4_159528529619625.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 121,412

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $77.35 to $78.33, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
July 16, 2020 Filed Jul 20, 2020 22:48 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 300 $75.98 $22,794.00
Disclosure

SEC source: 0001666071-20-000210 · wf-form4_159528529619625.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 122,812

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $75.89 to $76.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
July 02, 2020 Filed Jul 6, 2020 21:51 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 100 $69.64 $6,964.00
Disclosure

SEC source: 0001666071-20-000204 · wf-form4_159407224881693.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 123,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
July 02, 2020 Filed Jul 6, 2020 21:51 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 480 $68.98 $33,110.40
Disclosure

SEC source: 0001666071-20-000204 · wf-form4_159407224881693.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 123,212

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $68.53 to $69.20, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
July 02, 2020 Filed Jul 6, 2020 21:51 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,420 $67.99 $96,545.80
Disclosure

SEC source: 0001666071-20-000204 · wf-form4_159407224881693.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 123,692

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $67.50 to $68.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:07 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 1,140 $74.39 $84,804.60
Disclosure

SEC source: 0001666071-20-000187 · wf-form4_159242800782543.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 125,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $73.88 to $74.72, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:07 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 560 $73.21 $40,997.60
Disclosure

SEC source: 0001666071-20-000187 · wf-form4_159242800782543.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 126,252

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $72.59 to $73.54, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:07 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 300 $71.69 $21,507.00
Disclosure

SEC source: 0001666071-20-000187 · wf-form4_159242800782543.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 126,812

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $71.40 to $72.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
June 02, 2020 Filed Jun 3, 2020 21:56 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 100 $75.24 $7,524.00
Disclosure

SEC source: 0001666071-20-000163 · wf-form4_159122135419846.xml · nonDerivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 127,112

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
June 02, 2020 Filed Jun 3, 2020 21:56 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 500 $74.37 $37,185.00
Disclosure

SEC source: 0001666071-20-000163 · wf-form4_159122135419846.xml · nonDerivative · entry 3

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 127,212

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $74.15 to $74.62, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
June 02, 2020 Filed Jun 3, 2020 21:56 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 600 $73.58 $44,148.00
Disclosure

SEC source: 0001666071-20-000163 · wf-form4_159122135419846.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 127,712

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $73.14 to $74.11, inclusive.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
June 02, 2020 Filed Jun 3, 2020 21:56 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 800 $72.15 $57,720.00
Disclosure

SEC source: 0001666071-20-000163 · wf-form4_159122135419846.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 128,312

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the trustee of the 2013 Scott Grimes GRAT UAD (the "GRAT") on November 15, 2019, as amended March 12, 2020.

F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $71.64 to $72.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5) to this Form 4.

F3 · ownership.nature: The reportable securities are held by the GRAT.

Read SEC document
May 27, 2020 Filed May 27, 2020 22:03 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 9,447 $66.50 $628,225.50
Disclosure

SEC source: 0001666071-20-000151 · wf-form4_159061699889053.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,166

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for PSUs that vested on May 25, 2020.

F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $66.41 to $67.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

Read SEC document
May 25, 2020 Filed May 27, 2020 22:03 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionPerformance Stock Unit · Derivative 19,688 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000151 · wf-form4_159061699889053.xml · derivative · entry 4

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,374

Underlying: Common Stock · 19,688 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019. Twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU vested on May 25, 2020, 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification.

F5 · derivative.expiration_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019. Twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU vested on May 25, 2020, 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification.

Read SEC document
May 25, 2020 Filed May 27, 2020 22:03 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionCommon Stock 19,688 Not disclosed Not disclosed
Disclosure

SEC source: 0001666071-20-000151 · wf-form4_159061699889053.xml · nonDerivative · entry 1

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,613

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
May 21, 2020 Filed May 23, 2020 01:29 UTC Cardlytics, Inc. CDLX · Entity 7603 SaleCommon Stock 150 $67.83 $10,174.52
Disclosure

SEC source: 0001666071-20-000149 · wf-form4_159019734968767.xml · nonDerivative · entry 2

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,925

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs granted on May 20, 2020.

Read SEC document
May 20, 2020 Filed May 23, 2020 01:29 UTC Cardlytics, Inc. CDLX · Entity 7603 Exercise / conversionRestricted Stock Units · Derivative 355 $0.00 $0.00
Disclosure

SEC source: 0001666071-20-000149 · wf-form4_159019734968767.xml · derivative · entry 5

Grimes Scott D. · CIK 0001617486 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 355 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.

F5 · derivative.exercise_date: The RSUs are immediately vested.

F5 · derivative.expiration_date: The RSUs are immediately vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.